Asia Pacific multiple sclerosis drugs market will grow by 6.5% annually with a total addressable market cap of $33.56 billion over 2120-2027 owing to the growing prevalence of multiple sclerosis (MS), the rise in funding for multiple sclerosis research, and increasing approvals of novel MS drugs.
Highlighted with 35 tables and 54 figures, this 110-page report “Asia Pacific Multiple Sclerosis Drugs Market 2020-2027 by Drug Type (Immunomodulators, Immunosuppressants), Drug Class, Drug Category (Large-molecule, Small-molecule), Route of Administration (Oral, Parenteral), MS Type (RRMS, PPMS, SPMS, PRMS), Distribution Channel, and Country: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific multiple sclerosis drugs market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific multiple sclerosis drugs market in every aspect of the classification from perspectives of Drug Type, Drug Class, Drug Category, Route of Administration, MS Type, Distribution Channel, and Country.
Based on Drug Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Immunomodulators
o Copaxone
o Avonex/Plegridy
o Gilneya
o Tysabri
o Betaseron/Extavia
o Tecifidera
o Rebif
o Ampyra
o Other Immunomodulators
• Immunosuppressants
o Aubagio
o Lemtrada
o Ocrelizumab
o Zinbryta
o Other Immunosuppressants
Based on Drug Class, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Monoclonal Antibodies
• Interferon Beta
• Sphingosine 1 Phosphate Receptor Modulators
• Mixed Polymers
• NF-κB Inhibitor
• Pyrimidine Synthesis Inhibitor
• Corticosteroids
• Adrenocorticotropic Hormone
• Other Drug Classes
Based on Drug Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Large-molecule Drugs
• Small-molecule Drugs
Based on Route of Administration, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Oral Administration
• Parenteral Administration
Based on MS Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Relapsing-remitting MS (RRMS)
• Primary-progressive MS (PPMS)
• Secondary-progressive MS (SPMS)
• Progressive-relapsing MS (PRMS)
Based on Distribution Channel, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of key national markets by Drug Type, Route of Administration, and Distribution Channel over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbvie, Inc.
Acorda Therapeutics Inc.
Bayer AG
Biogen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Merck KgaA
Mylan NV
Novartis AG
Pfizer Inc.
Sanofi SA
Teva Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 33
2.5 Porter’s Fiver Forces Analysis 37
3 Segmentation of Asia Pacific Market by Drug Type 41
3.1 Market Overview by Drug Type 41
3.2 Immunomodulators 43
3.3 Immunosuppressants 45
4 Segmentation of Asia Pacific Market by Drug Class 47
4.1 Market Overview by Drug Class 47
4.2 Monoclonal Antibodies 49
4.3 Interferon Beta 50
4.4 Sphingosine 1 Phosphate Receptor Modulators 51
4.5 Mixed Polymers 52
4.6 NF-κB Inhibitor 53
4.7 Pyrimidine Synthesis Inhibitor 54
4.8 Corticosteroids 55
4.9 Adrenocorticotropic Hormone 56
4.10 Other Drug Classes 57
5 Segmentation of Asia Pacific Market by Drug Category 58
5.1 Market Overview by Drug Category 58
5.2 Large-molecule Drugs 60
5.3 Small-molecule Drugs 61
6 Segmentation of Asia Pacific Market by Route of Administration 62
6.1 Market Overview by Route of Administration 62
6.2 Oral Administration 64
6.3 Parenteral Administration 65
7 Segmentation of Asia Pacific Market by MS Type 66
7.1 Market Overview by MS Type 66
7.2 Relapsing-remitting MS (RRMS) 68
7.3 Primary-progressive MS (PPMS) 69
7.4 Secondary-progressive MS (SPMS) 70
7.5 Progressive-relapsing MS (PRMS) 71
8 Segmentation of Asia Pacific Market by Distribution Channel 72
8.1 Market Overview by Distribution Channel 72
8.2 Hospital Pharmacies 74
8.3 Retail Pharmacies 75
8.4 Online Pharmacies 76
9 Asia-Pacific Market 2020-2027 by Country 77
9.1 Overview of Asia-Pacific Market 77
9.2 China 80
9.3 Japan 82
9.4 India 85
9.5 Australia 87
9.6 South Korea 89
9.7 Rest of APAC Region 91
10 Competitive Landscape 93
10.1 Overview of Key Vendors 93
10.2 New Product Launch, Partnership, Investment, and M&A 96
10.3 Company Profiles 97
Abbvie, Inc. 97
Acorda Therapeutics Inc. 99
Bayer AG 100
Biogen Inc. 101
Bristol-Myers Squibb Company 102
F. Hoffmann-La Roche Ltd. 103
Merck KgaA 104
Mylan NV 105
Novartis AG 106
Pfizer Inc. 107
Sanofi SA 108
Teva Pharmaceutical Industries Ltd. 109
RELATED REPORTS 110
Table 1. Snapshot of Asia Pacific Multiple Sclerosis Drugs Market in Balanced Perspective, 2020-2027 17
Table 2. Growth Rate of World GDP, 2020-2022 21
Table 3. World Health Spending by Region, $ bn, 2013-2020 28
Table 4. Price Comparison of Commonly Used Multiple Sclerosis Medications 31
Table 5. Main Adverse Effects of Multiple Sclerosis Drugs 32
Table 6. Main Product Trends and Market Opportunities in Asia Pacific Multiple Sclerosis Drugs Market 33
Table 7. Asia Pacific Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 41
Table 8. Asia Pacific Multiple Sclerosis Drugs Market: Immunomodulators by Drug, 2017-2027, $ mn 44
Table 9. Asia Pacific Multiple Sclerosis Drugs Market: Immunosuppressants by Drug, 2017-2027, $ mn 46
Table 10. Asia Pacific Multiple Sclerosis Drugs Market by Drug Class, 2017-2027, $ mn 47
Table 11. Asia Pacific Multiple Sclerosis Drugs Market by Drug Category, 2017-2027, $ mn 58
Table 12. Asia Pacific Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 62
Table 13. Asia Pacific Multiple Sclerosis Drugs Market by MS Type, 2017-2027, $ mn 66
Table 14. Asia Pacific Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 72
Table 15. APAC Multiple Sclerosis Drugs Market by Country, 2017-2027, $ mn 78
Table 16. China Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 81
Table 17. China Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 81
Table 18. China Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 81
Table 19. Japan Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 84
Table 20. Japan Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 84
Table 21. Japan Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 84
Table 22. India Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 86
Table 23. India Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 86
Table 24. India Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 86
Table 25. Australia Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 88
Table 26. Australia Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 88
Table 27. Australia Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 88
Table 28. South Korea Multiple Sclerosis Drugs Market by Drug Type, 2017-2027, $ mn 90
Table 29. South Korea Multiple Sclerosis Drugs Market by Route of Administration, 2017-2027, $ mn 90
Table 30. South Korea Multiple Sclerosis Drugs Market by Distribution Channel, 2017-2027, $ mn 90
Table 31. Multiple Sclerosis Drugs Market in Rest of APAC by Country/Region, 2017-2027, $ mn 92
Table 32. Abbvie, Inc.: Company Snapshot 97
Table 33. Abbvie, Inc.: Business Segmentation 97
Table 34. Abbvie, Inc.: Product Portfolio 98
Table 35. Abbvie, Inc.: Revenue, 2017-2019, $ mn 98
